HSA & FSA eligible

Tirzepatide Plus is a once-weekly GIP (glucose-dependent insulinotropic polypeptide) receptor and GLP-1 (glucagon-like peptide-1) receptor agonist, representing a new class of medicines studied for the treatment of obesity. Tirzepatide is a single peptide that triggers the body’s receptors for GIP and GLP-1, two natural incretin hormones. Cyanocobalamin will help increase energy.

GIP has decreased food intake and increased energy expenditure, resulting in weight reductions. Combined with a GLP-1 receptor agonist, it has a more significant effect on glucose and body weight effects.

Wegovy, Ozempic, Rybelsus

Semaglutide is a Glucagon-like peptide-1 (GLP-1) produced by the gut. It increases insulin production, a hormone that lowers the blood sugar level while inhibiting glucagon secretion, which is a hormone that raises blood sugar, reduces appetite and energy intake while delaying gastric emptying. It was first developed in 2012 by Novo Nordisk as a longer-acting option to Liraglutide. In 2017 this drug was approved as an anti-diabetic medication used to treat type 2diabetes and obesity. In June 2021, it got approved for chronic weight management in obese individuals with a (BMI) ≥ 30 kg/m2) or overweight (initial BMI ≥ 27 kg/m2) with at least one weight-related comorbidity.

What does that mean to me?

  • Reduces food intake by lowering appetite.
  • Slows food digestion in the stomach.
  • Decrease body fat percentage.
  • Weight loss.
  • Decreased cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease.
  • Lower HbA1c levels.
Facebook
Twitter
LinkedIn
Pinterest
Vital Infusions & Performance

Vital Infusions & Performance

Social Media

Facebook
Twitter
LinkedIn
Pinterest

Popular Posts

Get The Latest Updates

Quick Call